Stock A288330 BRIDGE BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Bridge Biotherapeutics, Inc.

Equities

A288330

KR7288330004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
2,320 KRW +0.65% Intraday chart for Bridge Biotherapeutics, Inc. -1.69% -29.38%
Mar. 28 Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade CI
Mar. 26 Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade CI
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 1.99999872 billion in funding CI
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy CI
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC CI
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis CI
Bridge Biotherapeutics, Inc.(KOSDAQ:A288330) dropped from S&P Global BMI Index CI
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting CI
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis CI
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401 CI
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis CI
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022 CI
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877 CI
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022 CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 2.99997 billion in funding from a group of investors CI
Bridge Biotherapeutics to Sell Shares to Raise $38 Million MT
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 48.59976 billion in funding from a group of investors CI
Bridge Biotherapeutics, Inc. Presents Preclinical Data of BBT-207 at the AACR Annual Meeting 2022 CI
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics CI
Bridge Biotherapeutics, Inc. Announces Initiation of the Phase I Clinical Trial for BBT-401 in China CI
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology Virtual Congress 2021 CI
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis CI
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for Bbt-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site CI

Chart Bridge Biotherapeutics, Inc.

Chart Bridge Biotherapeutics, Inc.
More charts

Company Profile

Bridge Biotherapeutics, Inc. is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The products mainly consist of ulcerative colitis medicine BBT-401, autoxin inhibitor BBT-877, non-small cell lung cancer medicine BBT-176, and others. The Company is also involved in the manufacture of basic pharmaceuticals and biologicals.
Sector
Biotechnology & Medical Research
Calendar
2024-08-08 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BRIDGE BIOTHERAPEUTICS, INC. Stock Bridge Biotherapeutics, Inc.
-29.38% 41.46M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.52% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.38% 106B
BIONTECH SE Stock BioNTech SE
-12.64% 22.24B
ARGENX SE Stock argenx SE
+0.44% 21.25B
GENMAB A/S Stock Genmab A/S
-4.18% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.58% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.41% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-23.95% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A288330 Stock
  4. News Bridge Biotherapeutics, Inc.
  5. Bridge Biotherapeutics to Sell Shares to Raise $38 Million
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW